5/20/2022  1:44:28 PM Chg. +0.160 Volume Bid1:47:43 PM Ask1:44:28 PM Market Capitalization Dividend Y. P/E Ratio
19.250EUR +0.84% 42,348
Turnover: 810,647.100
19.255Bid Size: 57 19.265Ask Size: 11 658.62 mill.EUR 0.00% -

Business description

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
 

Management board & Supervisory board

CEO
Dr. Jean-Paul Kress
Management board
Sung Lee, Dr. Malte Peters, Dr. Roland Wandeler
Supervisory board
Dr. Marc Cluzel, Dr. George Golumbeski, Krisja Vermeylen, Michael Brosnan, Sharon Curran, Wendy Johnson
 

Company data

Name: MorphoSys AG
Address: Semmelweisstr. 7,D-82152 Martinsried/Planegg
Phone: +49-89-89927-0
Fax: +49-89-89927-222
E-mail: info@morphosys.de
Internet: www.morphosys.de
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 69.88%
IPO date: 3/9/1999

Investor relations

Name: Dr. Julia Neugebauer
IR phone: +49-89-89927-26972
IR Fax: -
IR e-mail: investors@morphosys.com

Company calendar

CW 32 | 8/3/2022 Interim Report 2nd Quarter/6 Months
CW 47 | 11/16/2022 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
69.88%
Baillie Gifford & Co
 
6.23%
Royalty Pharma PLC
 
3.91%
Schroders plc
 
3.03%
Invesco Ltd.
 
3.00%
T. Rowe Price Group, Inc.
 
2.99%
Artisan Partners Asset Management Inc.
 
2.95%
Templeton Funds Trust
 
2.85%
JPMorgan Chase & Co.
 
2.72%
Others
 
2.45%